ArticleInternational journal of women's health2025
Hysteroscopic Myomectomy for Type 2 Submucosal Myoma Pretreated by HIFU and Mifepristone Treatment: A Case Report and Literature Review.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential expression of estrogen and progesterone receptors before and after surgery in endometrial cancer and analysis of recurrence prediction model.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hysteroscopic myomectomy is the first-line treatment for the removal of submucosal myoma in women facing fertility requirements. However, in the face of large diameter type 2 submucosal myoma, patients are at greater risk of complications such as uterine perforation and fluid overload during hysteroscopy. When the diameter of type 2 submucous myoma is greater than 4cm, the three-phase treatment of high intensity focused ultrasound (HIFU), drugs and hysteroscopy is effective and safe. We shared a case of a 30-year-old non-pregnant woman, who had a history of uterine submucous myoma for more than 4 years with symptoms of heavy menstruation, prolonged menstruation and secondary severe anemia. The patient's initial pelvic magnetic resonance results suggested a type 2 uterine submucous myoma with a diameter of more than 4cm. We first performed HIFU on the patient, followed by the patient's oral intake of mifepristone tablets for 3 months, and prior to hysteroscopic surgery, the patient's fibroid type was shifted to type 0, and finally successfully completed hysteroscopic myomectomy (HM). Finally, we conclude that when the diameter of type 2 submucosal myoma exceeds 4 cm, preoperative application of HIFU combined with drug treatment should be considered to maximize the reduction of fibroids, improve symptoms such as anemia and dysmenorrhea, reduce the time required for hysteroscopic surgery, and improve the safety of surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.